FREE Case Review (866) 588-0600

Gadolinium Deposition Disease Lawsuit

The U.S. Food & Drug Administration (FDA) is warning about the risk of gadolinium retention in patients who undergo MRIs with gadolinium-based contrast agents (GBCAs).

Our lawyers are filing lawsuits for people who were diagnosed with gadolinium deposition disease, sometimes referred to as gadolinium storage condition, after undergoing an MRI or other similar medical procedure which involved use of a contrast agent.

Free Confidential Lawsuit Evaluation: If you or a loved one has been diagnosed with gadolinium deposition disease or gadolinium storage condition, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.

What’s the Problem?

Gadolinium is used as an ingredient in contrast agents which are injected into patients undergoing magnetic resonance imaging (MRI) procedures to enhance the image created by the MRI. There is evidence that gadolinium does not leave the body as quickly as the drug manufacturers promised. Instead, it is being retained in various parts of the body, putting the patient at risk for gadolinium toxicity.

Mayo Clinic Study Finds Gadolinium in Brains of MRI Patients

Researchers at the Mayo Clinic in Rochester, Minnesota, found direct evidence of gadolinium deposition in neuronal tissues in patients who had undergone MRI scans with gadolinium-based contrast agents. The evidence was gathered from a cohort of patients who had donated their bodies to medical research after undergoing multiple gadolinium contrast-enhanced MRI exams over the course of their lives. Brain tissue samples from these patients was then compared to donors who had never been administered a GBCA. The patients exposed to the gadolinium contrast had measurable quantities of gadolinium left over in their brain tissue, whereas those never exposed to gadolinium had none, the researchers found.

“Given that these agents are administered millions of times every year, this is an important discovery,” said study author, Laurence Eckel, M.D., radiologist, Mayo Clinic. The findings were published online in the journal Radiology.

Gadolinium Deposition Disease Symptoms

    • Bone pain
    • Joint pain
    • Skin and subcutaneous tissue burning pain
    • “Chemo brain” or “brain fog”
    • Skin changes
    • Thickening / discoloration of the skin
    • “Pins and needles” in the arms and legs
    • Headache

    Gadolinium Deposition Disease vs. Gadolinium Storage Condition: What’s the Difference?

    Gadolinium Storage Condition – Refers to situations in which a person has normal renal function but has been diagnosed with excess gadolinium in their body.

    Gadolinium Deposition Disease – Refers to situations in which a person has normal or adequate renal function but develops persistent and/or painful symptoms anywhere from a few hours to several weeks after being injected with a GBCA.

    Do I have a Gadolinium Deposition Disease Lawsuit?

    The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in gadolinium lawsuits. We are handling individual litigation nationwide and currently accepting new gadolinium deposition disease / gadolinium storage condition cases in all 50 states.

    Free Case Evaluation: Again, if you or a loved one has been diagnosed with gadolinium deposition disease or gadolinium storage condition, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
*
*
*

Awards & recognition